CBD and appetite: trials point to a decrease
CBD does not make you hungry the way THC does. In clinical trials at high doses, the effect reported most often is the reverse: decreased appetite, in 9 to 29% of patients at 20 mg per kilo per day. At the amounts in an over-the-counter product, no effect on hunger has been measured, and no appetite claim is permitted in France.
Key takeaways
- The "munchies" come from THC activating the CB1 receptor; in cell models, CBD tends to dampen that same receptor.
- According to a 2022 review of 11 controlled trials, CBD tends to have an "anorexigenic" effect, mainly at high doses.
- Decreased appetite (21%) is one of the most common side effects listed in the Epidyolex leaflet.
- Wellness products are nowhere near these doses; EFSA's provisional safe level is about 2 mg a day.
THC and CBD: opposite actions on the same receptor
Appetite is partly regulated by the endocannabinoid system, a network of receptors and messengers in the brain and the gut, whose main receptor in the brain is CB1. How the system works is explained in our article on the endocannabinoid system.
THC activates CB1 directly, hence the hunger associated with cannabis. Medicine makes use of this elsewhere: in the United States, dronabinol, a synthetic THC, has been approved since 1985 and is indicated for anorexia with weight loss in patients with AIDS.
CBD acts another way. In 2015, a team at Dalhousie University showed in cells that CBD behaves as a negative allosteric modulator of the CB1 receptor. Without activating the receptor itself, it weakens the effect of the molecules that do, THC among them. In a 2012 study in rats, CBD reduced the amount of food eaten and CBN increased it. Laboratory data like these do not carry over directly to humans. CBN is covered on our dedicated page.
What human trials show
The most complete synthesis is a systematic review by Joaquim Pinto and Fátima Martel, published in 2022 in Clinical Drug Investigation. It covers 11 placebo-controlled trials: six in children with severe epilepsies, one in autism, one in type 2 diabetes, one in Covid-19 and two in healthy volunteers. Most report decreased appetite or weight and a few report no change. A single trial reports an increase.
The four large trials in Dravet and Lennox-Gastaut syndromes used 20 mg of CBD per kilo per day. Decreased appetite affected 9 to 29% of patients on CBD, against 1 to 17% on placebo. Epidyolex is the only authorised CBD-based medicine, and its European product information lists decreased appetite (21%) among the most common side effects between 10 and 25 mg/kg/day. At 20 or 25 mg/kg/day, 21% of patients lost at least 5% of their body weight, against 7% at 10 mg/kg/day. These trials are covered in detail in our article on Epidyolex and epilepsy.
The review's authors point out the limitations themselves. In five of the epilepsy trials, some children were also on topiramate, an antiepileptic known to reduce appetite. According to the Epidyolex leaflet, combining CBD with valproate makes decreased appetite more frequent. The authors rate the risk of bias as a concern for most trials, and it is not always clear whether the patient or the parents reported on appetite.
What about the doses in a wellness product?
The scale is very different. For an adult of 70 kg, 20 mg/kg/day comes to 1,400 mg of CBD a day. In February 2026 EFSA set a provisional safe level of 0.0275 mg/kg/day for supplements of CBD at least 98% pure, about 2 mg a day for the same adult. The level does not cover people under 25, pregnant or breastfeeding women, or people on medication. Our article on EFSA's reference dose explains the calculation.
| Context | Daily dose | Reported effect on appetite |
|---|---|---|
| Epilepsy trials | 20 mg/kg, i.e. 1,400 mg for 70 kg | Decrease in 9 to 29% of patients |
| Type 2 diabetes trial | 100 mg twice a day | No effect on appetite or weight |
| Healthy volunteers | 600 mg | Increase in 2 of 16 participants |
| EFSA provisional safe level | about 2 mg | Not studied |
No trial has shown any effect on hunger, up or down, at the amounts usually found in a CBD oil or flower. What some consumers describe are individual impressions without a control group, and a change in schedule, sleep or habits may be enough to account for them. Our article on CBD side effects lists the effects observed, dose by dose.
What the law allows sellers to say
Saying that a product acts on appetite, whether it increases hunger or curbs it, is a health claim. Regulation (EC) No 1924/2006 allows only claims that are authorised and entered in the EU register, and none of them concerns CBD. Under Article L5111-1 of the French Public Health Code, a product presented as having curative or preventive properties also becomes a medicinal product by presentation.
Swallowing CBD raises a separate issue. On 20 May 2026 the French Ministry of Agriculture restated that foods containing CBD are not authorised and must be withdrawn from the market, food supplements included. Our article on CBD regulation in 2026 gives the full picture.
Frequently asked questions
No. THC stimulates appetite by activating the CB1 receptor. CBD leaves that receptor unactivated and, in cell models, tends to dampen its activation. High-dose clinical trials most often report decreased appetite.
No, and it may not be presented as one. The decrease in appetite was seen in patients on very high doses, often while taking other medicines that also favour it. The Epidyolex leaflet lists it as a side effect to monitor; it appears nowhere as a benefit.
No trial has shown it at the doses of a wellness product, which stay far below those of clinical studies. If your appetite or weight changes for a lasting period, see a doctor and mention the products you take.
A 2012 study in rats found that CBN increased food intake, the reverse of what CBD did. No human data confirm this, and CBN has no authorised claim either.
Written by the Phytogrammes team
Each journal article draws on cited primary sources: ANSM, EFSA, EUR-Lex and peer-reviewed publications. Product profiles are distinguished from documented laboratory results. Our approach.
Article published on . CBD is not a medicine.